Last reviewed · How we verify
Samarium 153
At a glance
| Generic name | Samarium 153 |
|---|---|
| Also known as | Samarium sm 153 lexidronam pentasodium, Quadramet |
| Sponsor | Radiation Therapy Oncology Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain (PHASE1)
- Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer (PHASE1)
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer (PHASE3)
- A Dose Finding Study to Treat Bone Tumor(s) (PHASE1)
- Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
- A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy (PHASE1)
- Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer (PHASE1, PHASE2)
- Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Samarium 153 CI brief — competitive landscape report
- Samarium 153 updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI